Accession Therapeutics doses first patient in new cancer immunotherapy trial
Esme Needham | November 26, 2025 | News story | Research and Development | Accession Therapeutics, Oncology
Biopharmaceutical company Accession Therapeutics has announced the dosing of the first patient in the phase 1 clinical trial of TROCEPT-01 (ATTR-01), its new solid tumour treatment.
The treatment utilises Accession’s proprietary TROCEPT platform to deliver a genetically encoded immune checkpoint inhibitor (anti-PD-L1) directly to tumour cells. This enables the cancer cells themselves to secrete therapeutic proteins within the microenvironment of the tumour, fighting the tumour while minimising systemic exposure and damage. Preclinical studies of TROCEPT-01 have demonstrated its capacity for drug concentration at the tumour site rather than surrounding tissues, minimising harm and lengthening the therapeutic window.
TROCEPT-01 is administered intravenously. Its design aims to improve issus with existing checkpoint inhibitor therapies by improving response rates in unresponsive tumours, and reducing adverse events caused by lower tumour-site drug concentration. The trial, which was conducted at clinical sites across the UK, focused on patients with advanced carcinomas who had undergone at least one prior course of treatment.
Bent Jakobsen, CEO of Accession Therapeutics, said: “In TROCEPT, we have created a unique, highly versatile platform that enables novel drugs to be made inside cancer cells. The platform gives us multiple opportunities to generate valuable products to transform outcomes for cancer patients. TROCEPT-01 has the potential to expand the indications where checkpoint inhibitors have been successful.”
Accession specialises in oncology, with a focus on tumour-targeted immunotherapies delivered through its TROCEPT platform. The company has raised $70m to advance the TROCEPT technology and related programmes since 2021.
